Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer. - Suppr | 超能文献

Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer.

作者信息

Buzdar Aman U, Hortobagyi Gabriel N

机构信息

The University of Texas, M.D. Anderson Cancer Center, Houston TX, USA.

出版信息

Cancer Treat Rev. 2003 Oct;29(5):449-52. doi: 10.1016/s0305-7372(03)00167-1.

DOI:10.1016/s0305-7372(03)00167-1

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer.

Cancer Treat Rev. 2003 Oct;29(5):449-52. doi: 10.1016/s0305-7372(03)00167-1.

2

Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.

Cancer Treat Rev. 2003 Oct;29(5):453-6. doi: 10.1016/s0305-7372(03)00164-6.

3

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

J Clin Oncol. 2013 Jul 10;31(20):2593-9. doi: 10.1200/JCO.2012.46.9841. Epub 2013 Jun 3.

4

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.

Semin Oncol. 1995 Dec;22(6 Suppl 15):18-23.

5

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.

Breast Cancer Res Treat. 2012 Apr;132(2):609-19. doi: 10.1007/s10549-011-1913-4. Epub 2011 Dec 21.

6

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

BMC Cancer. 2007 Apr 12;7:63. doi: 10.1186/1471-2407-7-63.

7

Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.

Clin Breast Cancer. 2002 Dec;3(5):333-40. doi: 10.3816/CBC.2002.n.036.

8

Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

Clin Cancer Res. 2001 Dec;7(12):3934-41.

9

Optimizing dose-dense regimens for early-stage breast cancer.

Nat Rev Clin Oncol. 2010 Dec;7(12):678-9. doi: 10.1038/nrclinonc.2010.188.

10

Weekly taxanes--a leap forward or a minute progress?

Acta Oncol. 2004;43(1):5-7. doi: 10.1080/02841860310023101.